Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Interesting risk
View:
Post by DJDawg on Jun 18, 2024 7:03pm

Interesting risk

The way this is all timed is interesting. The email announcing the PP said that the paperwork (contract) had to be sent to the company by Friday. With the spate of recent NR's they have created anticipation. By doing the AGM and the virtual presention tomorrow they are taking a chance. If the updates between now and Friday are same old same old (BTD in later 2024 for example, no more details) then a chunk of the wealthy people who sign up for these PPs could just choose not to join. After all, the price always drifts down anyways unless there is some true driver. If I had a bunch of cash around, my options would be PP on Friday for 0.22 plus warrant or buy a bunch at 0.16 in a few weeks. Which is a better deal? 0.16 I think.

So they are taking a risk that the news this week will inspire enough confidence up to Friday to get enough cash from the PP.

Does that make sense? They have timed it in such a way to lead up to a big PP or to a really bad PP.
Comment by Alamir1111 on Jun 18, 2024 7:39pm
Let's hope the new pp participants have better luck than the one expiring in august
Comment by Gooseybear on Jun 18, 2024 8:26pm
The PR announcements regarding the impacts of Ruthherin are compelling. Given Roger's history., I would believe that he would be conservative in his statements. Thus, I'm extremely excited and loaded up.
Comment by riverrrow on Jun 18, 2024 9:01pm
For some reason I believe the closing date is June 28, and they've been known to close as much as a week after the proposed closing date.
Comment by Tapps21 on Jun 18, 2024 9:45pm
Well, it's getting close to gut check time and within the next 24 hours we will hopefully have a better understanding of the direction we are heading. Especially financing. As long as the company is honest with us. The news has been outstanding and all the pieces are slowly coming together. we just need that one big Pharma believer to sink its teeth in deep. I am a believer and unfortunately ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250